Project Grant R01CA313650
Award Date 5/8/26
Completion Date 4/30/31
Dollars Obligated $558K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating glioma risk and improving patient outcomes by integrating germline and somatic genetics analysis. The project addresses critical gaps in understanding the functional relevance of 30 known germline...
- The National Cancer Institute awarded the Regents of the University of Minnesota a $386,612 Project Grant effective August 13, 2025, through July 31, 2027, under the Cancer Cause and Prevention Research program (CFDA 93.393). This R21 exploratory/developmental grant supports research investigating how social and structural determinants of health (SSDOH) contribute to accelerated biological aging and cancer risk disparities among middle-aged and older adults. The project leverages existing data...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Jackson Laboratory a $704,636 Project Grant on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on pre-leukemic hematopoietic stem cell (HSPC) clonal selection by the adaptive immune system through April 30, 2031. The research deliverables include mechanistic studies defining the stages at which CD4+ T cells control pre-leukemic HSPC selection and evaluation of...
- Federal Grant Award Summary The University of Minnesota, through its Office of Sponsored Projects Administration, received a $399,852 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective May 1, 2026 through April 30, 2028. The research project investigates circulating senescent-associated secretory phenotype (SASP) proteins and their relationship to age-related health outcomes in cancer survivors. The project...
- Federal Cooperative Agreement Summary Mayo Clinic Arizona has been awarded $704,622 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to conduct preclinical studies for the immunoprevention of multiple myeloma. The award, effective August 15, 2025, through May 31, 2027, supports research examining how various factors—including diet, microbiome composition, systemic inflammation, and clonal hematopoiesis—contribute to an inflamed bone marrow microenvironment...
- Federal Grant Award Summary Mayo Clinic received a $367,731 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 12, 2026, with a completion date of April 30, 2031. The grant supports research investigating ADAR1 (Adenosine Deaminase Acting on RNA 1) protein's role in DNA replication and its potential as a therapeutic target for breast cancer treatment. The research focuses on the nuclear ADAR1P110 isoform's...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $645,245 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded April 1, 2026, with a completion date of March 31, 2031. This five-year award supports research investigating the effect of DDX41 mutations on hematopoiesis during aging, specifically examining the role of these mutations in myelodysplastic syndromes (MDS), a group of bone marrow...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $235,491 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective May 1, 2026, through April 30, 2031. This award supports biomedical research and training infrastructure focused on investigating the biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations (MCAs). The funded research will conduct a large-scale...